and Mutations in Myelodysplastic Syndromes (MDS): Clonal Architecture and Impact on Outcomes

Overview

Journal Leuk Lymphoma

Specialties Hematology
Oncology

Date 2019 Jan 9

PMID 30618304

Citations 11

Authors

Nour Abuhadra

Sudipto Mukherjee

Karam Al-Issa

Vera Adema

Cassandra M Hirsch

Anjali Advani

Bartlomiej Przychodzen

Ahed Makhoul

Hassan Awada

Jaroslaw P Maciejewski

Mikkael A Sekeres

Aziz Nazha

Affiliations

Soon will be listed here.

Citing Articles

Myelodysplastic Neoplasms (MDS): The Current and Future Treatment Landscape.

Karel D, Valburg C, Woddor N, Nava V, Aggarwal A Curr Oncol. 2024; 31(4):1971-1993.

PMID: 38668051 PMC: 11049094. DOI: 10.3390/curroncol31040148.

Understanding the Continuum between High-Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia.

Zavras P, Sinanidis I, Tsakiroglou P, Karantanos T Int J Mol Sci. 2023; 24(5).

PMID: 36902450 PMC: 10002503. DOI: 10.3390/ijms24055018.

Gene mutation analysis using next-generation sequencing and its clinical significance in patients with myeloid neoplasm: A multi-center study from China.

Li J, Pei L, Liang S, Xu S, Wang Y, Wang X Cancer Med. 2023; 12(8):9332-9350.

PMID: 36799265 PMC: 10166913. DOI: 10.1002/cam4.5690.

The genetics of myelodysplastic syndromes and the opportunities for tailored treatments.

Kontandreopoulou C, Kalopisis K, Viniou N, Diamantopoulos P Front Oncol. 2022; 12:989483.

PMID: 36338673 PMC: 9630842. DOI: 10.3389/fonc.2022.989483.

Personalized Risk Schemes and Machine Learning to Empower Genomic Prognostication Models in Myelodysplastic Syndromes.

Awada H, Gurnari C, Durmaz A, Awada H, Pagliuca S, Visconte V Int J Mol Sci. 2022; 23(5).

PMID: 35269943 PMC: 8911403. DOI: 10.3390/ijms23052802.

References

Nazha A, Al-Issa K, Hamilton B, Radivoyevitch T, Gerds A, Mukherjee S . Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes. Leukemia. 2017; 31(12):2848-2850. DOI: 10.1038/leu.2017.266. View

Tefferi A, Vardiman J . Myelodysplastic syndromes. N Engl J Med. 2009; 361(19):1872-85. DOI: 10.1056/NEJMra0902908. View

Greenberg P, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F . Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120(12):2454-65. PMC: 4425443. DOI: 10.1182/blood-2012-03-420489. View

Damm F, Chesnais V, Nagata Y, Yoshida K, Scourzic L, Okuno Y . BCOR and BCORL1 mutations in myelodysplastic syndromes and related disorders. Blood. 2013; 122(18):3169-77. DOI: 10.1182/blood-2012-11-469619. View

Nazha A, Narkhede M, Radivoyevitch T, Seastone D, Patel B, Gerds A . Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes. Leukemia. 2016; 30(11):2214-2220. DOI: 10.1038/leu.2016.138. View